Studies for Parkinson's Disease patients with cognitive impairment

Parallel-Group Study to Assess the Effect of Rasagiline on Cognition in Patients With Parkinson's Disease

Purpose:  This is a 24-week, multicenter, randomized, double-blind, placebo-controlled, add-on, parallel-group study to evaluate the effect of rasagiline on cognitive function in adults with mild cognitive impairment (MCI) in Parkinson's disease (PD-MCI).

Duration: 24 weeks

Study design: Randomized, double-blind, placebo-controlled

Inclusion Criteria:
Nondemented man or woman 45 through 75 years of age with idiopathic PD
Mild cognitive impairment in Parkinson's disease (PD-MCI)
Medically stable outpatient, based on the investigator's judgment
The patient is on a stable dopaminergic medication regimen for ≥ 30 days before entering the study
Other inclusion criteria apply.

Exclusion Criteria:
Clinically relevant history of vascular disease (eg, stroke)
History of melanoma
History of deep brain stimulation (DBS)
Impaired hepatic function, based on the investigator's judgment
Psychosis or is receiving antipsychotic treatment
Clinically significant or unstable medical or surgical condition that may preclude safe and complete study participation, based on the investigator's judgment
Other exclusion criteria apply.

Last modified: Jul 29, 2013
ID=x13917